Priority Research Papers:
Tumor antigen CA125 suppresses antibodydependent cellular cytotoxicity ADCC via direct antibody binding and suppressed Fcγ receptor engagement
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 2392 views | Full Text 4921 views
James Bradford Kline1, Rina P. Kennedy1, Earl Albone1, Qimin Chao1, Shawn Fernando1, Jennifer M. McDonough1, Katherine Rybinski1, Wenquan Wang1, Elizabeth B. Somers1, Charles Schweizer1, Luigi Grasso1 and Nicholas C. Nicolaides1
1 Morphotek Inc., Exton, PA, USA
Correspondence to:
Nicholas C. Nicolaides, email:
Keywords: CA125, ADCC, farletuzumab, Fc-γ receptor, ovarian cancer
Received: May 15, 2017 Accepted: May 19, 2017 Published: July 07, 2017
Abstract
Cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of tumor-shed antigen CA125/MUC16 on suppressing IgG1-mediated antibody-dependent cellular cytotoxicity (ADCC). This evidence stems from prespecified subgroup analysis of a Phase 3 clinical trial testing farletuzumab, a monoclonal antibody to folate receptor alpha, plus standard-of-care carboplatin-taxane chemotherapy in patients with recurrent platinum-sensitive ovarian cancer. Patients with low serum CA125 levels treated with farletuzumab demonstrated improvements in progression free survival (HR 0.49, p = 0.0028) and overall survival (HR 0.44, p = 0.0108) as compared to placebo. Farletuzumab’s pharmacologic activity is mediated in part through ADCC. Here we show that CA125 inhibits ADCC by directly binding to farletuzumab that in turn perturbs Fc-γ receptor engagement on effector cells.